EMPRISE-Study
EMPRISE-Study
Search
Connect with your heart
If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
Vetmedin®
Treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation).
Five facts everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
Patient Documentary
People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Be At The Heart Of Every Breakthrough
Now is the time to cultivate your unique tech talent at a leading pharmaceutical company.
Patient documentary - From diagnosis to everyday living
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
BI 765845: Heart disease modulator | Myocardial infarction
BI 765845: Heart disease modulator | Myocardial infarction